We are raising £5,000,000 for Phase 2 and Phase 3 cancer vaccine trials. Phase I testing in mice has been completed and the results have been very encouraging. While many have tried and failed to develop a cancer vaccine, this approach is different because it is generic and does not use a specific antigen as its target but targets them all. The construct itself bears additional sequences to boost innate immunity and neo-antigens (new sequences bear no homology to anything in the databases) to mount strong immune responses. It also uses ATRA as an immunomodulator. This approach is can theoretically be used for all cancers. It has been tested on 4 different cancers with 6 different animal models bearing different cancer genes. This approach enhances immune responses to all the antigens presented by the cancer cell and not just one as is found with the other specific vaccines in use.
Let me know if you would like additional information and/or would like a call with the founder.
David Fletcher
Ready to Ask For Funding for your company?
Post a Funding Request